Clinical trials: Unresectable Intrahepatic Cholangiocarcinoma
Unresectable Intrahepatic Cholangiocarcinoma
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC.
- Trial name
- NCT02994251
- Testing
- gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Intrahepatic Cholangiocarcinoma
Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
The purpose of this study is to find out if the combination of trans-arterial chemoembolization (LC or ONCOZENE BEAD) plus infusional chemotherapy is safe and more effective than just receiving the infusional chemotherapy alone.
- Trial name
- DELTIC (NCT01648023)
- Testing
- LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo, Gem-Cis or Gem-Carbo
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Robert C. Martin
Intrahepatic Cholangiocarcinoma
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
The study planned to evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in…
- Trial name
- SIRCCA (NCT02807181)
- Testing
- Cisplatin-gemcitabine, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 89 people
- Sponsor
- Sirtex Medical
Bile Duct Neoplasms, Colorectal Neoplasms
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
Due to discontinuation of the Codman C3000 pump, an alternate device is necessary to continue serving patients in need of hepatic arterial infusion chemotherapy.
- Trial name
- NCT04276090
- Testing
- Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter., Hepatic artery infusion pump floxuridine and dexamethasone, Systemic chemotherapy for colorectal liver metastases
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Michael J Cavnar, MD
Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery.
- Conditions
- Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
- Trial name
- NCT00553332
- Testing
- selumetinib, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma
Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
The purpose of this study is to use both, liver pump treatment and systemic chemotherapy, to assess the effects this type of treatment has on the patient and the tumor.
- Conditions
- Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma
- Trial name
- NCT01862315
- Testing
- Floxuridine (FUDR), dexamethasone, Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gallbladder Carcinoma, Metastatic Cholangiocarcinoma
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
This randomized phase II trial studies how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places in the body (metastatic) and cannot be removed by surgery…
- Conditions
- Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03201458
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 41 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3)…
- Conditions
- Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma
- Trial name
- NCT03267940
- Testing
- PEGPH20, CIS, GEM
- Where
- 36 sites in United States, South Korea and 1 more
- Volunteers
- 85 people
- Sponsor
- Halozyme Therapeutics
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
This phase II trial studies how well pevonedistat alone or in combination with chemotherapy (paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver.
- Conditions
- Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04175912
- Testing
- Carboplatin, Paclitaxel, Pevonedistat
- Where
- 419 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Intrahepatic Cholangiocarcinoma, Resectable Intrahepatic Cholangiocarcinoma
A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma
This research study is evaluating the use of radiation therapy in combination with chemotherapy as a possible treatment for intrahepatic cholangiocarcinoma, a rare form of gastrointestinal cancer.
- Trial name
- NCT02256982
- Testing
- Gemcitabine, Cisplatin, Surgery
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
This phase II trial studies the efficacy and safety of systemic induction of mFOLFIRINOX, followed by hepatic arterial infusion (HAI) floxuridine-dexamethasone administered concurrently with systemic mFOLFIRI in treating patients…
- Conditions
- Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04251715
- Testing
- Dexamethasone, Floxuridine, Implanted Medical Device
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma
Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer
This randomized phase III trial studies how well gemcitabine hydrochloride and cisplatin with or without radiation therapy work in treating patients with localized liver cancer that cannot be removed by surgery.
- Trial name
- NCT02200042
- Testing
- Image Guided Radiation Therapy
- Where
- 34 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- NRG Oncology
Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
This phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body.
- Conditions
- Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8
- Trial name
- NCT03768414
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel
- Where
- 692 sites in United States
- Volunteers
- 452 people
- Sponsor
- SWOG Cancer Research Network
Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
This phase II trial studies how well ramucirumab works in treating patients with previously treated biliary cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced)…
- Conditions
- Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Stage III Gallbladder Cancer AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7
- Trial name
- NCT02520141
- Testing
- Laboratory Biomarker Analysis, Ramucirumab
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Unresectable Intrahepatic Cholangiocarcinoma
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
- Trial name
- NCT04301778
- Testing
- Durvalumab, SNDX-6352
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
This phase II trial studies how well gemcitabine hydrochloride, cisplatin, and nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) work in treating patients with biliary cancers (which includes the gallbladder…
- Conditions
- Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7
- Trial name
- NCT02392637
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer of the Gallbladder, Cancer of the Biliary Tract
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
This is a Phase II trial of the combination of oxaliplatin (Eloxatin) and capecitabine (Xeloda), known as XELOX, in participants with unresectable or recurrent cholangiocarcinoma, including carcinoma of the gallbladder or biliary…
- Trial name
- NCT00338988
- Testing
- Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center